Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.
Sign Up to like & getrecommendations! Published in 2021 at "Clinics and research in hepatology and gastroenterology"
DOI: 10.1016/j.clinre.2020.11.013
Abstract: OBJECTIVE α-fetoprotein is often used in the diagnosis of hepatocellular carcinoma (HCC). However, there are currently less efficient and highly specific biomarkers to distinguish AFP-negative HCC from liver cirrhosis (LC) patients. PATIENTS AND METHODS We… read more here.
Keywords: cirrhosis patients; afp negative; hcc; negative hcc ... See more keywords
Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1072775
Abstract: Background Early diagnosis for α-fetoprotein (AFP) negative hepatocellular carcinoma (HCC) remains a critical problem. Metabolomics is prevalently involved in the identification of novel biomarkers. This study aims to identify new and effective markers for AFP… read more here.
Keywords: hepatocellular carcinoma; negative hcc; negative hepatocellular; hcc ... See more keywords